Eun K Yang 10/12/12, OPTR star analyst per Yahoo...
Jefferies maintained a Buy rating on Optimer Pharmaceuticals (NASDAQ: OPTR), a company that focuses on the discovery, development and commercialization of anti-infective products, with one marketed drug for the treatment of diarrhea, DIFICID (fidaxomicin/OPT-80).
"While preannounced 3Q12 gross Dificid sales of $18.4M (~+2% q/q) are soft, OPTR's new strategy to drive further Dificid growth is reassuring," said analyst Eun K. Yang.
To address Dificid cost issues and enable patient access, Optimer Pharmaceuticals CEO offered a new strategy, including a 25 percent discount to acute care hospitals, New Technology Add-On Payment, and a Dificid Rx Assist program.
Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.